346 related articles for article (PubMed ID: 10628376)
1. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
2. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.
Borgström P; Hillan KJ; Sriramarao P; Ferrara N
Cancer Res; 1996 Sep; 56(17):4032-9. PubMed ID: 8752175
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Melnyk O; Zimmerman M; Kim KJ; Shuman M
J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
[TBL] [Abstract][Full Text] [Related]
5. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
7. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
[TBL] [Abstract][Full Text] [Related]
10. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].
Wang F; Tian YH; Li L; Chen XF; Hu HH; Li CY; Huang Q
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Mar; 34(2):165-70. PubMed ID: 12006990
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
15. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
Kondo S; Asano M; Suzuki H
Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
[TBL] [Abstract][Full Text] [Related]
16. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
19. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
